For the quarter ending 2025-09-30, PROF made $5,289,000 in revenue. -$8,785,000 in net income. Net profit margin of -166.10%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue (note 11) | 5,289,000 | 2,211,000 | 2,621,000 | 2,670,000 |
| Cost of sales | 1,358,000 | 593,000 | 768,000 | 910,750 |
| Gross profit | 3,931,000 | 1,618,000 | 1,853,000 | 1,759,250 |
| Research and development | 5,418,000 | 6,098,000 | 4,808,000 | 4,241,250 |
| Selling, general and administrative | 7,426,000 | 9,326,000 | 8,211,000 | 5,783,500 |
| Total operating expenses | 12,844,000 | 15,424,000 | 13,019,000 | 10,024,750 |
| Operating loss | -8,913,000 | -13,806,000 | -11,166,000 | -8,265,500 |
| Net finance (income) expense | 122,000 | 343,000 | 445,000 | 359,000 |
| Net foreign exchange (gain) loss | 935,000 | -2,168,000 | 38,000 | 952,000 |
| Total other (income) expenses | 1,057,000 | -1,825,000 | 483,000 | 1,311,000 |
| Net loss before income taxes | -7,856,000 | -15,631,000 | -10,683,000 | -6,954,500 |
| Income tax expense | 100,000 | 78,000 | 41,000 | 36,000 |
| Deferred tax expense | 21,000 | -14,000 | - | -36,500 |
| Total income tax expense | 121,000 | 64,000 | 41,000 | -500 |
| Net loss attributed to shareholders for the period | -7,977,000 | -15,695,000 | -10,724,000 | -6,954,000 |
| Foreign currency translation adjustment | -808,000 | 2,713,000 | 103,000 | -705,750 |
| Net loss and other comprehensive loss for the period | -8,785,000 | -12,982,000 | -10,621,000 | -7,659,750 |
| Earnings per share, basic | 0.26 | 0.52 | 0.36 | 0.28 |
| Earnings per share, diluted | 0.26 | 0.52 | 0.36 | 0.28 |
| Weighted average number of shares outstanding, basic | 30,104,497 | 30,053,142 | 30,041,735 | 6,191,375.75 |
| Weighted average number of shares outstanding, diluted | 30,104,497 | 30,053,142 | 30,041,735 | 6,191,375.75 |
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)